Homepage
U.S.
International
Log In
Log Out
CNNMoney
Video
Portfolio
Home
Business
Markets
Investing
Economy
Tech
Personal Finance
Small Business
Luxury
Media
Twitter
Facebook
Today is July 01, 2024. All times in Eastern Daylight Time.
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
06/01/2024 - 08:00 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with len...
more
»
1
...
128
129
130
131
132
133
134
135
136
137
138
« Previous
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire